Erickson Living Begins Construction of New Continuing Care Retirement Community -- Lantern Hill

Print E-mail
By Marketwired - Medical and professional cialis Healthcare   
Tuesday, 11 February 2014 10:44

BALTIMORE, MD--(Marketwired - Feb 11, 2014) - Erickson Living, a leading developer and canadian healthcare viagra sales manager of continuing care retirement communities (CCRCs) in the United States, has started construction of a new 540,000-square-foot CCRC at 535 Mountain Avenue in New Providence, New Jersey. 

"A retirement community in northwest Union County is a natural extension of Erickson Living's commitment to serving the state of New Jersey," said Chris Emmett, Vice President of Regional Operations for Erickson Living. "Lantern Hill is a premier property, and we embrace the opportunity to serve those who will live and real cialis without prescription work at this distinctive community."

Erickson Living brings a wide scope of resources and fda approved cialis expertise in operating entrance fee CCRCs. The company's mission and viagra non prescription culture of caring, commitment, and professionalism is recognized nationwide and cialis soft tablets will serve as the foundation for creating an exceptional resident experience. Erickson Living's gold standard of excellence, which has driven high occupancies, strong resident and discount cialis online employee satisfaction, and investment in the healthcare and real viagra pharmacy prescription cialis brand name services of its communities, will be an important part of its formula for success. 

On November 17, Erickson Living selected Wohlsen Construction as the general contractor for its eighteenth community. The project architect for Lantern Hill is Lantz-Boggio Architects of Englewood, Colorado.

The planned community will consist of five inter-connected buildings, including 275 newly designed spacious independent living apartment homes and cialis tablets 85 continuing care residences offering assisted living, memory care, long term care and short term rehabilitation. Residents will also enjoy a fitness facility with an indoor swimming pool, as well as a wide range of services, including restaurants, housekeeping, and social/ recreational programs.

There is a strong demand for desirable senior living in northern New Jersey. The senior population in this geographic area is growing rapidly and canada meds viagra this location remains a destination of choice for seniors from across the country. According to the Blueprint for Healthy Aging in New Jersey (written by the State of New Jersey, Department of Health and canada viagra pharmacies scam Human Services), all of the North Jersey counties have populations aged 60+ years that are projected to increase a minimum of 35 percent from 2000 to 2025.

Lantern Hill is the third Erickson Living community in New Jersey; others are located in Morris and purchase real name brand viagra Monmouth counties. The current plan is for the CCRC to open in the second half of 2015. The on-site sales office will open in the spring 2014.

Photo:Preliminary Site Plan of Lantern Hill  

About Erickson Living:  Erickson Living is a nation-leading developer and manager of continuing-care retirement communities, headquartered in Baltimore, Maryland. Further information regarding Erickson Living is available at

About Lantern Hill:Lantern Hill is located in the township of New Providence (Union County), New Jersey. The nearly 21-acre site is the perfect northern/central New Jersey retirement destination. More information about the community can be found at:

Documents and/or Photos available for this release:

Site Plan Rendering of Lantern Hill

To view supporting documents and/or photos, go to and enter Release ID: 367603

Read more

BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!


BioMedReports PlasmaTech Announces Initiation of Enrollment of MuGard® Trial for Afinitor®; Ironwood Initiates Phase I Clini...
BioMedReports Vanda Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus; Aerpio Announces Pub...
BioMedReports Bristol-Myers Squibb: ‘This Is the Fastest Approval I’ve Seen’...